1
|
Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018; 9:5097. [PMID: 30504837 PMCID: PMC6269466 DOI: 10.1038/s41467-018-07603-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 10/30/2018] [Indexed: 12/25/2022] Open
Abstract
Tumours often evade CD8 T-cell immunity by downregulating TAP. T-cell epitopes associated with impaired peptide processing are immunogenic non-mutated neoantigens that emerge during tumour immune evasion. The preprocalcitonin (ppCT)16-25 neoepitope belongs to this category of antigens. Here we show that most human lung tumours display altered expression of TAP and frequently express ppCT self-antigen. We also show that ppCT includes HLA-A2-restricted epitopes that are processed by TAP-independent and -dependent pathways. Processing occurs in either the endoplasmic reticulum, by signal peptidase and signal peptide peptidase, or in the cytosol after release of a signal peptide precursor or retrotranslocation of a procalcitonin substrate by endoplasmic-reticulum-associated degradation. Remarkably, ppCT peptide-based immunotherapy induces efficient T-cell responses toward antigen processing and presenting machinery-impaired tumours transplanted into HLA-A*0201-transgenic mice and in NOD-scid-Il2rγnull mice adoptively transferred with human PBMC. Thus, ppCT-specific T lymphocytes are promising effectors for treatment of tumours that have escaped immune recognition.
Collapse
Affiliation(s)
- Aurélie Durgeau
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France.,ElyssaMed, Paris Biotech Santé, 75014, Paris, France
| | - Yasemin Virk
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Gwendoline Gros
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Elodie Voilin
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Stéphanie Corgnac
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Fayçal Djenidi
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Jérôme Salmon
- CNRS (Centre National de la Recherche Scientifique) UMR 8122, Gustave Roussy, Faculté de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Julien Adam
- INSERM U 981, Gustave Roussy, Faculté de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France
| | - Vincent de Montpréville
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France.,Service d'Anatomie Pathologique, Centre Chirurgical Marie-Lannelongue, 92350, Le-Plessis-Robinson, France
| | - Pierre Validire
- Service d'Anatomie Pathologique, Institut Mutualiste Montsouris, 75014, Paris, France
| | - Soldano Ferrone
- Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
| | - Salem Chouaib
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France.,Thumbay Institute for Precision Medicine, Gulf Medical University, Ajman, 4184, UAE
| | - Alexander Eggermont
- Cancer Institute, Gustave Roussy Cancer Campus, Grand Paris, 94805, Villejuif, France
| | - Jean-Charles Soria
- Department of Drug Development (DITEP), Gustave Roussy, 94805, Villejuif, France
| | - François Lemonnier
- Département Endocrinologie, Métabolisme et Diabète, Equipe Immunologie des Diabètes, INSERM U1016, 75014, Paris, France
| | - Eric Tartour
- INSERM U970, Paris Cardiovascular Research Centre, Université Paris-Descartes, Sorbonne Paris Cité, Equipe Labellisée Ligue Contre le Cancer, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, 75015, Paris, France
| | - Nathalie Chaput
- Laboratory of Immunomonitoring in Oncology, and CNRS-UMS 3655 and INSERM-US23, Gustave Roussy Cancer Campus, Villejuif, France.,Faculté de Pharmacie, University Paris-Sud, F-92296, Chatenay-Malabry, France
| | - Benjamin Besse
- Département de Médecine, Gustave Roussy, 94805, Villejuif, France
| | - Fathia Mami-Chouaib
- INSERM UMR 1186, Integrative Tumour Immunology and Genetic Oncology, Gustave Roussy, EPHE, PSL, Fac. de Médecine, Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France.
| |
Collapse
|
2
|
Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B, Mami-Chouaib F. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 2015. [PMID: 25725111 DOI: 10.4049/jimmunol.1402711.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non-small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103(+) TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8(+)CD103(+) TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1-PD-L1 interaction. These findings emphasize the role of CD8(+)CD103(+) tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti-PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Collapse
Affiliation(s)
- Fayçal Djenidi
- INSERM Unité 1186, 94805 Villejuif, France; Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France
| | - Julien Adam
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; INSERM Unité 981, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France
| | - Aïcha Goubar
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; INSERM Unité 981, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France
| | - Aurélie Durgeau
- INSERM Unité 1186, 94805 Villejuif, France; Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France
| | - Guillaume Meurice
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; Institut de Cancérologie Gustave Roussy, Plateforme de Bioinformatique, 94805 Villejuif, France
| | - Vincent de Montpréville
- INSERM Unité 1186, 94805 Villejuif, France; Centre Chirurgical Marie-Lannelongue, Service d'Anatomie Pathologique, 92350 Le-Plessis-Robinson, France
| | - Pierre Validire
- Institut Mutualiste Montsouris, Service d'Anatomie Pathologique, 75014 Paris, France; and
| | - Benjamin Besse
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; Département de Médecine, Institut de Cancérologie Gustave Roussy, 95805 Villejuif, France
| | - Fathia Mami-Chouaib
- INSERM Unité 1186, 94805 Villejuif, France; Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France;
| |
Collapse
|
3
|
Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B, Mami-Chouaib F. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. J I 2015; 194:3475-86. [PMID: 25725111 DOI: 10.4049/jimmunol.1402711] [Citation(s) in RCA: 408] [Impact Index Per Article: 45.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Fayçal Djenidi
- INSERM Unité 1186, 94805 Villejuif, France; Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France
| | - Julien Adam
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; INSERM Unité 981, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France
| | - Aïcha Goubar
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; INSERM Unité 981, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France
| | - Aurélie Durgeau
- INSERM Unité 1186, 94805 Villejuif, France; Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France
| | - Guillaume Meurice
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; Institut de Cancérologie Gustave Roussy, Plateforme de Bioinformatique, 94805 Villejuif, France
| | - Vincent de Montpréville
- INSERM Unité 1186, 94805 Villejuif, France; Centre Chirurgical Marie-Lannelongue, Service d'Anatomie Pathologique, 92350 Le-Plessis-Robinson, France
| | - Pierre Validire
- Institut Mutualiste Montsouris, Service d'Anatomie Pathologique, 75014 Paris, France; and
| | - Benjamin Besse
- Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France; Département de Médecine, Institut de Cancérologie Gustave Roussy, 95805 Villejuif, France
| | - Fathia Mami-Chouaib
- INSERM Unité 1186, 94805 Villejuif, France; Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France; Université Paris-Sud, 91400 Orsay, France;
| |
Collapse
|